Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Shire PLC Add to portfolio

LON100:SHP, Feb 16, 06:20 UTC

Latest LON100:SHP News

Filter your feed

Apply Filter

Wednesday, January 23


News

Noteworthy Stocks to Watch for: AMREP Corporation (NYSE:AXR) & Shire plc (NASDAQ:SHPG)

SHP

Noteworthy Stocks to Watch for: AMREP Corporation (NYSE:AXR) & Shire plc (NASDAQ:SHPG). AMREP CORP.is a real estate developer and builder of housing, national distributor of magazines and a provider of subscription fulfillment services for publishers. It is the developer and major builder of single-family homes at Rio Rancho, New Mexico and more recently has entered the Denver, Colorado home-building market. The 1 analysts offering 12-month price forecasts for AMREP Corp have a median target of 9.25, with a high estimate of 9.25 and a low estimate of 9.25.

Read Full Details

Topics:
  • Business
  • Financial

Friday, January 11


News

Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange

SHP

On January 8, 2019, Takeda Pharmaceutical Company Limited (TSE: 4502, NYSE: TAK), a Japanese joint-stock corporation (“Takeda”), acquired all of the issued and to-be-issued share capital of Shire pursuant to a Scheme of Arrangement under Article 125 of the Companies (Jersey) Law 1991, as amended. As a result, Shire and SAIIDAC became wholly-owned subsidiaries of Takeda, and the listings of Shire’s common shares on the London Stock Exchange and of American Depositary Shares (“ADSs”) representing Shire’s common shares on the NASDAQ Global Market were terminated. The factors described in the context of such forward-looking statements herein could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this release. Risk Factors”, and in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in ‘ITEM1A: Risk Factors’, and in Shire’s subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.takeda.com, www.shire.com and www.sec.gov). Except to the extent otherwise required by applicable law, neither Takeda nor Shire nor SAIIDAC undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, January 09


News

De-listing and cancellation of trading of Shire Shares

SHP

Citigroup Global Markets Limited (joint financial adviser to Shire) (US) Chris Hite +1 212 816 6000 Cary Kochman (UK) Jan Skarbek Andrew Seaton (Corporate Broking) +44 207 986 4000. Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin Philippe Gallone David Kitterick Peter Moorhouse (Corporate Broking) +44 207 425 8000. Takeda Elissa Johnsen (Media – outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media – within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media – within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306. No profit forecasts or estimates. Unless expressly stated otherwise, nothing in this Announcement (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement in this Announcement should be interpreted to mean that earnings or earnings per share or dividend per share for Takeda or Shire, as appropriate, for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share or dividend per share for Takeda or Shire, as appropriate. If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, January 08


News

Takeda Pharmaceutical completes Shire acquisition - Shire PLC (NASDAQ:SHPG)

SHP

Takeda Pharmaceutical completes Shire acquisition. Jan. 8, 2019 3:11 AM•SA Editor Yoel Minkoff. The rapidly changing pharmaceutical landscape reached another milestone today as Takeda (NYSE:TAK) became a top 10 global drugmaker by completing its $62B acquisition of Shire (NASDAQ:SHPG). A flurry of multibillion-dollar pharma deals is happening as traditional companies turn to acquisitions to replenish their drug pipelines and combat expiring patents. Already in 2019, Eli Lilly agreed to buy Loxo Oncology for $8B, just days after Bristol-Myers Squibb scooped up Celgene for $74B. Recommended for you:. SA Stock Market news.

Read Full Details

Topics:
  • Business
  • Financial

Monday, January 07


News

How Takeda's $62 Billion Shire Deal Reshapes the Pharma World

SHP

(Bloomberg) -- A major step in the rapidly changing global pharmaceutical landscape takes place Tuesday with the closing of Takeda Pharmaceutical Co.’s $62 billion acquisition of Shire Plc. Takeda’s purchase was the world’s biggest announced acquisition of 2018, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S. It’s part of a larger shift in the industry as drugmakers scramble to consolidate, seeking to bulk up to survive the increasing pressure from stricter regulations on drug prices and looming patent expirations. The Takeda deal has already been trumped in size by Bristol-Myers Squibb Co.’s $74 billion agreement last week to buy Celgene Corp. Here’s how the supersized Takeda will look in the increasingly evolving pharmaceutical landscape:. The company will also hold a unique position in being a big pharmaceutical company with a focus on rare diseases acquired from Shire’s portfolio.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, January 03


News

Court sanction of the Scheme

LSE SHP

Shire Christoph Brackmann (Investor Relations) christoph.brackmann@shire.com +41 41 288 41 29 Scott Burrows (Investor Relations) scott.burrows@shire.com +41 41 288 41 95 Sun Kim (Investor Relations) sun.kim@shire.com +1 617 588 8175 Katie Joyce (Media) kjoyce@shire.com +1 781 482 2779. Takeda Elissa Johnsen (Media – outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media – within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media – within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306. Such risks and uncertainties include, but are not limited to, the possibility that a possible combination will not be pursued or consummated, failure to obtain necessary regulatory approvals or to satisfy any of the other conditions to the possible combination if it is pursued, adverse effects on the market price of Takeda’s or Shire’s ordinary shares and on Takeda’s or Shire’s operating results because of a failure to complete the possible combination, failure to realise the expected benefits of the possible combination, negative effects relating to the announcement of the possible combination or any further announcements relating to the possible combination or the consummation of the possible combination on the market price of Takeda’s or Shire’s ordinary shares, significant transaction costs and/or unknown liabilities, general economic and business conditions that affect the combined companies following the consummation of the possible combination, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business combinations or disposals and competitive developments. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement. All forward-looking statements attributable to Takeda or Shire or any person acting on either company’s behalf are expressly qualified in their entirety by this cautionary statement.

Read Full Details

Topics:
  • Business
  • Financial

Friday, December 21


News

Form 8.3 - Shire plc

SHP

Business Wire21 December 2018, 15:00 GMT. FORM 8.3. The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (b)Rights to subscribe for new securities (including directors’ and other employee options). Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, December 20


News

The Baupost Group UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited

SHP BPOST

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (b)Rights to subscribe for new securities (including directors’ and other employee options). Details, including nature of the rights concerned and relevant percentages:. Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:.

Read Full Details

Topics:
  • Business
  • Financial
News

Form 8.3 - Shire plc

SHP

Business Wire20 December 2018, 15:00 GMT. FORM 8.3. The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (b)Rights to subscribe for new securities (including directors’ and other employee options). Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, December 19


News

Form 8.3 - Shire plc

SHP

Business Wire19 December 2018, 15:00 GMT. FORM 8.3. The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (b)Rights to subscribe for new securities (including directors’ and other employee options). Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:.

Read Full Details

Topics:
  • Business
  • Financial